Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.

Item

http://www.wikidata.org/entity/Q38176625

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.

@en

type

Item

label

Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.

@en

prefLabel

Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.

@en

P1476

Dendritic cell vaccination in pediatric gliomas: lessons learnt and future perspectives.

@en

P2093

Johannes Rachor

http://www.w3.org/2001/XMLSchema#string

Matthias Wölfl

http://www.w3.org/2001/XMLSchema#string

Paul G Schlegel

http://www.w3.org/2001/XMLSchema#string

Susanne C Schreiber

http://www.w3.org/2001/XMLSchema#string

P2860

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPED.2013.00012

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matthias Eyrich

P577

2013-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259628565

http://www.w3.org/2001/XMLSchema#string

P698

24400258

http://www.w3.org/2001/XMLSchema#string

P932

3860891

http://www.w3.org/2001/XMLSchema#string